Your browser doesn't support javascript.
loading
The GRPR Antagonist [99mTc]Tc-maSSS-PEG2-RM26 towards Phase I Clinical Trial: Kit Preparation, Characterization and Toxicity.
Abouzayed, Ayman; Borin, Jesper; Lundmark, Fanny; Rybina, Anastasiya; Hober, Sophia; Zelchan, Roman; Tolmachev, Vladimir; Chernov, Vladimir; Orlova, Anna.
Afiliação
  • Abouzayed A; Department of Medicinal Chemistry, Uppsala University, 751 83 Uppsala, Sweden.
  • Borin J; Department of Protein Science, KTH Royal Institute of Technology, 114 17 Stockholm, Sweden.
  • Lundmark F; Department of Medicinal Chemistry, Uppsala University, 751 83 Uppsala, Sweden.
  • Rybina A; Department of Nuclear Medicine, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634009 Tomsk, Russia.
  • Hober S; Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, 634050 Tomsk, Russia.
  • Zelchan R; Department of Protein Science, KTH Royal Institute of Technology, 114 17 Stockholm, Sweden.
  • Tolmachev V; Department of Nuclear Medicine, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634009 Tomsk, Russia.
  • Chernov V; Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, 634050 Tomsk, Russia.
  • Orlova A; Department of Immunology, Genetics and Pathology, Uppsala University, 752 37 Uppsala, Sweden.
Diagnostics (Basel) ; 13(9)2023 May 02.
Article em En | MEDLINE | ID: mdl-37175001

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Diagnostics (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Suécia País de publicação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Diagnostics (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Suécia País de publicação: Suíça